As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML.

Read Professor Hughes' CML publications of the month: March 2024

Clinical CML papers

• Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? – Review
  Kantarjian H et al. Leukemia, March 2024 (epub ahead of print)
• Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia positive clone or variant Philadelphia translocations
  Claudiani S et al. Am J Hematol, March 2024 (epub ahead of print) – open access publication
• Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
  Brioli A et al. Leukemia, March 2024 (epub ahead of print) – open access publication
• European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission
  Mahon FX et al. J Clin Oncol, March 2024 (epub ahead of print)
• Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
  Smith BD et al. Leuk Res, March 2024 (epub ahead of print)
• High efficacy and safety of asciminib in a chronic myeloid leukemia patient with chronic kidney disease following renal transplantation
  Uchida Y et al. Intern Med, March 2024 – open access publication
• A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
  Bonifacio M et al. Blood Cancer J, March 2024 – open access publication
• Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI Stopping Trial HALF
  Zácková D et al. Leukemia, March 2024 (epub ahead of print) – open access publication
• The role of molecular or cytogenetic response as a favourable prognostic factor before hematopoietic cell transplantation for chronic myeloid leukemia
  Medeiros GRO et al. Transplant Cell Ther, March 2024 (epub ahead of print)
• The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia
  Haddad FG et al. Am J Hematol, March 2024 (epub ahead of print) – open access publication
• A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia
  Galimberti S et al. Pharmaceutics, March 2024 – open access publication
• The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia
  Nieves Saez Perdomo, M et al. Hematol Rep, March 2024 – open access publication
• Clinical outcomes of patients with lymphoid blast phase of chronic myeloid leukemia treated with CAR T-cell therapy
  Liu Y et al. Blood Cancer J, March 2024 – open access publication
  

Scientific CML papers

• Mutations in myeloid transcription factors and activated signalling genes predict chronic myeloid leukemia outcomes
  Perusini MA et al. Blood Adv, March 2024 (epub ahead of print)
• Clinical pharmacokinetics and drug-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia: A clinical perspective – Review
  Cheng F et al. Crit Rev Oncol Hematol, March 2024

Pediatric CML papers

• Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
  Behrens YL et al. Haematologica, March 2024 – open access publication
• Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED Cohort
  Stiehler S et al. Haematologica, March 2024 (epub ahead of print) – open access publication
  
• Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patient with chronic myeloid leukemia
  Abdallah AM et al. Leuk Lymphoma, March 2024 (epub ahead of print)
• Chronic spontaneous urticarial as the presenting factor in a paediatric case of chronic myeloid leukemia
  Sutton KM et al. Pediatr Blood Cancer, March 2024
• Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: Results from the Phase I part of Study ITCC054/COG AMML1921
  Brivio E et al. J Clin Oncol, March 2024 – open access publication